SCHEMBL16067289

SCHEMBL16067289

Cc1cc(C)c2[nH]cc(C=O)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.59
TRIM33 Q9UPN9 1/20 0.59
PIM3 Q86V86 6/20 0.49
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MPI P34949 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ERN1 O75460 1/20 0.39
AR P10275 1/20 0.39
CYP2A6 P11509 2/20 0.39
IMPDH2 P12268 1/20 0.39
PIM1 P11309 4/20 0.38
PIM2 Q9P1W9 1/20 0.38
GRIN2D O15399 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL674053 0.82 TRIM24 (0.56) TRIM24TRIM33PIM3CYP1A2CYP2C19
SCHEMBL672970 0.82 TRIM24 (0.56) TRIM24TRIM33PIM3CYP1A2CYP2C19
SCHEMBL671315 0.82 TRIM24 (0.56) TRIM24TRIM33PIM3CYP1A2CYP2C19
SCHEMBL9732966 0.80 ALDH1A1 (0.56) TRIM24TRIM33CYP1A2CYP2C19MAPT
SCHEMBL13356952 0.79 CYP1A2 (0.38) TRIM24TRIM33PIM3CYP1A2CYP2C19
SCHEMBL20688241 0.76 MAPT (0.50) TRIM24TRIM33CYP1A2CYP2C19CYP3A4
SCHEMBL672635 0.74 TRIM24 (1.00) TRIM24TRIM33PIM3MAPTALDH1A1
SCHEMBL3247007 0.74 APP (0.48) TRIM24TRIM33CYP1A2CYP2C19CYP3A4
SCHEMBL29956158 0.73 TRIM24 (0.62) TRIM24TRIM33PIM3CYP1A2CYP2C19
SCHEMBL14690039 0.72 TRIM24 (0.44) TRIM24TRIM33PIM3CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968272-B1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2021-06-16 EP disclosed
EP-2968272-B1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2021-06-16 EP disclosed
US-10653670-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2020-05-19 US disclosed
US-10653670-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2020-05-19 US disclosed
US-20190290613-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION 2019-09-26 US disclosed
US-20190290613-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION 2019-09-26 US disclosed
US-10258605-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2019-04-16 US disclosed
US-10258605-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2019-04-16 US disclosed
US-20180193309-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION 2018-07-12 US disclosed
US-20180193309-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION 2018-07-12 US disclosed
US-20180193309-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION 2018-07-12 US disclosed
US-20160030389-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2016-02-04 US disclosed
US-20160030389-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2016-02-04 US disclosed
US-20160030389-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2016-02-04 US disclosed
WO-2014143125-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180193309-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING IDO1, FABP4, IDO2 TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885
US-20190290613-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING IDO1, FABP4, IDO2 TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885
US-20160030389-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING IDO1, FABP4, IDO2 TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885
US-10653670-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening IDO1, FABP4, IDO2 TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885
US-10258605-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening IDO1, FABP4, IDO2 TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.